-
1
Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
Published 2025-01-01Subjects: Get full text
Article -
2
Long-Term Safety and Effectiveness of Canakinumab in Patients with MKD/HIDS: Interim Analysis of the RELIANCE Registry
Published 2024-12-01Subjects: “…Canakinumab…”
Get full text
Article